Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 4/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18842313 | 0.89 | LMNA (0.34) | JAK3LMNATACR3XDHCNR1 | |
| SCHEMBL17640857 | 0.83 | BTK (0.39) | JAK3KRASBCL2A1BTKHSP90AA1 | |
| SCHEMBL17640855 | 0.81 | JAK3 (0.46) | JAK3ERBB2HSP90AA1HSP90AB1PDK1 | |
| SCHEMBL17634307 | 0.81 | JAK3 (0.47) | JAK3LMNAHSP90AA1HSP90AB1PDK1 | |
| SCHEMBL17640808 | 0.77 | CNR2 (0.50) | JAK3CNR1CNR2BCL2A1BTK | |
| SCHEMBL17640805 | 0.76 | HSP90AA1 (0.42) | JAK3KRASEGFRBCL2A1HSP90AA1 | |
| SCHEMBL16647117 | 0.75 | ERBB2 (0.45) | KRASERBB2EGFR | |
| SCHEMBL17640831 | 0.74 | KRAS (0.52) | KRASBCL2A1 | |
| SCHEMBL21402207 | 0.73 | ERBB2 (0.39) | JAK3LMNAKRASERBB2EGFR | |
| SCHEMBL17640830 | 0.73 | KRAS (0.48) | KRASBCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| US-9862701-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-9810690-B2 | Method for screening inhibitors of Ras | ARAXES PHARMA LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-9810690-B2 | Method for screening inhibitors of Ras | ARAXES PHARMA LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170131278-A1 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC | 2017-05-11 | — | — | US | disclosed |
| US-20170131278-A1 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC | 2017-05-11 | — | — | US | disclosed |
| WO-2017070256-A2 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| WO-2016049524-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | JAK3 3314/4885LMNA 603/4885TACR3 4407/4885 |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | JAK3 3314/4885LMNA 603/4885TACR3 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.